Influence of apolipoprotein A‐1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults

Meng, Qingguo; Pajukanta, Päivi; Valsta, Liisa; Aro, Antti; Pietinen, Pirjo; Tikkanen, Matti J.

doi:10.1046/j.1365-2796.1997.122139000.x

Cited by 23 publications

(24 citation statements)

References 26 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are not consistent with those reported by Meng et al (1997), Needham et al (1994), and Ma et al (2005), possibly due to differences in the sample groups between the studies (ethnicity, sex, etc.). We report here that the rs2070665 polymorphism is associated with Lp(α) levels (P < 0.05), which has not been found in other studies.…”

Section: Discussioncontrasting

confidence: 88%

Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to investigate the potential association between apolipoprotein A1 (APOA1) gene rs670, rs5069, and rs2070665 polymorphisms and dyslipidemia in the Kazakh population of Xinjiang, China. Matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MALDI-TOF-MS) was used to identify APOA1 (rs670, rs5069, and rs2070665) genotypes in 736 subjects (341 dyslipidemia patients and 395 control subjects). The frequencies of the CC genotype for rs1421085 were found to be 7.2% (obese group), 4.4% (overweight group), and 5.6% (control group). Polymorphisms of the three loci of the APOA1 gene in Kazakh subjects met Hardy-Weinberg equilibrium. The frequencies of the A allele for rs670 were found to be 14.3% (dyslipidemia group) and 12.7% (control group). The frequencies of the T allele for rs5069 and rs2070665 were: dyslipidemia group (7.2 and 30.1%, respectively) and control group (7.7 and 32.5%, respectively). Frequency distributions of the 3 types of genotypes and alleles of the three loci showed no statistically significant difference (P > 0.05). Significant differences were observed in lipoprotein (α) [Lp(α)] between patients with the rs2070665 CT + TT and CC genotypes (P < 0.05); however, none of the other relevant indicators differed significantly between the two genotypes. No significant association was identified between rs670 or rs5069 and the lipid-related metabolic indices assessed in the study. These findings indicate that the polymorphisms in the APOA1 gene (rs670, rs5069, and rs2070665) are not associated with dyslipidemia in the Kazakh population assessed in this study.

show abstract

Section: Discussioncontrasting

confidence: 88%

Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Up-regulation of the apoA-I promoter may lead to increased HDL production and increased very low-and low-density lipoprotein (LDL) clearance. Previous studies also showed an association between the apoA-I polymorphism and plasma triglyceride levels, the triglyceride level being lower in men with À75A [14,19].…”

Section: Introductionmentioning

confidence: 75%

“…DNA was extracted from peripheral blood from the 271 Hong Kong Chinese subjects. The apoA-I gene C83T and G-75A polymorphisms were screened using a PCR-based RFLP protocol [14]. The presence of the MspI restriction sites at À75 bp (G allele) and at +83 bp (C allele) in the 433 bp product resulted in four fragments of 209 bp, 113 bp, 66 bp and 45 bp.…”

Section: Methodsmentioning

confidence: 99%

“…Several genetically determined structural variants of apoA-I have been identified, and have allowed the characterisation of structure-function relationships in the protein [7]. 0167 A GYA mutation at position À75 of the apoA-I gene promoter occurs at a frequency of about 0.18 in Caucasian populations and has been associated with higher plasma HDL-cholesterol levels in several ethnic groups [8][9][10][11][12][13][14][15][16][17]. In vitro [18] and in vivo studies [15][16][17] have shown that the A substitution is associated with increased apoA-I gene expression, and elevated plasma apoA-I and HDL-cholesterol concentrations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels

Qing

Thomas

Tomlinson

2005

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…The genotype effect on circulating apo(a1) and HDL cholesterol levels is modulated by sex and environmental factors such as smoking (3,7,10). The differences in HDL cholesterol and apo(a1) levels among various genotypes of the apo(a1) gene are not modified by different diets, suggesting that the possible benefit is independent of fat and cholesterol intake (11).…”

mentioning

confidence: 99%

MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease.

et al. 2000

View full text Add to dashboard Cite

T he protective effect of HDL cholesterol and apolipoprotein A1 [apo(a1)] on the risk of coronary heart disease (CHD) is mediated mainly through the promotion of cholesterol efflux from peripheral cells (1). In addition, both HDL cholesterol and apo(a1) may have antioxidant, antithrombotic, and anti-inflammatory properties, which could have important antiatherogenic effects (1). The level of circulating HDL cholesterol and apo(a1) is dependent on sex, BMI, age (2), smoking (3), alcohol intake, and lipid-lowering medication (4). In addition, different variants in the apo(a1) gene can modify its expression and affect HDL cholesterol and apo(a1) levels (5,6).Restriction site polymorphisms have been identified at Ϫ75 bp in the promoter region and ϩ37 and ϩ83 bp in intron 1 of the apo(a1) gene. Polymorphisms at Ϫ75 and ϩ83 bp of the apo(a1) gene have been related to elevated levels of HDL cholesterol and apo(a1) in nondiabetic subjects (5-7), although not confirmed in all studies (8,9). Association of the ϩ83-bp polymorphism with elevated levels of HDL cholesterol has been stronger than that with the Ϫ75-bp polymorphism (6). The genotype effect on circulating apo(a1) and HDL cholesterol levels is modulated by sex and environmental factors such as smoking (3,7,10). The differences in HDL cholesterol and apo(a1) levels among various genotypes of the apo(a1) gene are not modified by different diets, suggesting that the possible benefit is independent of fat and cholesterol intake (11).So far, no studies have been published on the impact of the Ϫ75-and/or ϩ83-bp polymorphisms of the apo(a1) gene on HDL cholesterol and apo(a1) levels in patients with type 2 diabetes. To this aim, we screened nondiabetic and type 2 diabetic subjects with CHD for the Ϫ75-and ϩ83-bp polymorphisms of the apo(a1) gene. RESEARCH DESIGN AND METHODS SubjectsAll unrelated subjects (n = 641: 469 men, 172 women) participating in this study were R I G I N A L A R T I C L EOBJECTIVE -Elevated HDL cholesterol and its principal carrier protein apolipoprotein A1 [apo(a1)] are associated with reduced risk of coronary heart disease (CHD). No studies are available on the impact of the Ϫ75-bp and/or ϩ83-bp polymorphisms of the apo(a1) gene on HDL cholesterol and apo(a1) levels in patients with type 2 diabetes.RESEARCH DESIGN AND METHODS -We determined the prevalence of the Ϫ75-bp and ϩ83-bp polymorphisms of the apo(a1) gene by restriction fragment length polymorphism analysis among 308 unrelated nondiabetic subjects with CHD and among 251 unrelated patients with type 2 diabetes with CHD and in randomly selected 82 healthy men (CHD Ϫ ). RESULTS-The rare M1 Ϫ and M2 Ϫ allele frequencies of the apo(a1) gene were 23 and 1.8%, respectively, among control subjects; 20 and 1.5%, respectively, among nondiabetic subjects with CHD; and 22 and 2.6%, respectively, among patients with type 2 diabetes and CHD (NS). Nonsmoking nondiabetic subjects with CHD having the M2 ϩϪ genotype had higher HDL cholesterol (1.48 ± 0.19 vs. 1.23 ± 0.02 mmol/l, P Ͻ 0.01) and apo(a1) (1.43...

show abstract

Influence of apolipoprotein A‐1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults

Cited by 23 publications

References 26 publications

Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang

Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang

Association of two apolipoprotein A-I gene MspI polymorphisms with lipid and blood pressure levels

MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease.

Contact Info

Product

Resources

About